DrMichael Pulley

Enhancing rehabilitation in people with amyotrophic lateral sclerosis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis

A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With NewOnset Generalized Myasthenia Gravis

ALS Bitner Plante Initiative 2026

A non-interventional, post-authorisation safety study of patients treated with efgartigimod alfa

A Phase 3, Randomized, Double-Blind, Placebo -Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis

ALS Bitner Plante Initiative 2025

ALS Bitner Plante Initiative 2024

The ME&MG digital solution for autonomous assessment of Myasthenia Gravis: a validation study

A PHASE 3, OPEN-LABEL EXTENSION OF COURAGE-ALS (CY 5031)

Establishing the Natural History of Upper Motor Neuron-Dominant ALS and PLS

ALS Bitner Plante Initiative 2023

PLS Natural History Study (PNHS)

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis

ALS Bitner Plante Initiative 2022

A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)

ARGX-113-1802, A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Subcutaneously Administered Efgartigimod with rHuPH20 in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CTOA

ALS Bitner Plante Initiative 2021